Bamlanivimab reduces risk of COVID-19 Infection: JAMA Study

Bamlanivimab monotherapy reduces the incidence of COVID-19 infection, according to a clinical trial.;

Written By : MD Bureau

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-07-08 03:30 GMT | Update On 2021-07-08 06:06 GMT

Bamlanivimab therapy reduced the risk of COVID-19 in residents and staff of skilled nursing and assisted living facilities, according to a study published in the Journal of American Medical Association.

Ever since the outbreak of the COVID pandemic, healthcare workers have been trying their best to contain the infection. They are at high risk for developing the infection as close living environments, presymptomatic and asymptomatic transmission of SARS-CoV-2, and frequent staff contact required to meet the care needs of frail residents contributes to SARS-CoV-2 transmission. Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection from SARS-CoV-2 infection and COVID-19. With this background, investigators carried out a randomised clinical trial to determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities.

The study was a randomized, double-blind, single-dose, phase 3 trial that included a total of 1175 participants between August 2 to November 20, 2020. The participants were residents and staff at US skilled nursing and assisted living facilities. There was at least 1 confirmed SARS-CoV-2 index case and participants were randomized to receive a single intravenous infusion of bamlanivimab, 4200 mg (n = 588), or placebo (n = 587). The primary outcome was incidence of COVID-19 infection and mild or worse disease severity within 21 days of detection, within 8 weeks of randomization. Secondary outcomes included incidence of moderate or worse COVID-19 severity and incidence of SARS-CoV-2 infection.

According to the results of the study,

Bamlanivimab significantly reduced the incidence of COVID-19 in the prevention population compared with placebo

Five deaths attributed to COVID-19 were reported by day 57; all occurred in the placebo group.

Reported adverse events was 20.1% in the bamlanivimab group and 18.9% in the placebo group. The most common adverse events were urinary tract infection (reported by 12 participants [2%] who received bamlanivimab and 14 [2.4%] who received placebo) and hypertension (reported by 7 participants [1.2%] who received bamlanivimab and 10 [1.7%] who received placebo).

The trial clearly demonstrates that among residents and staff in skilled nursing and assisted living facilities, bamlanivimab monotherapy reduced the incidence of COVID-19 infection, suggesting the potential of bamlanivimab as a preventive intervention.

"Further research is needed to assess preventive efficacy with current patterns of viral strains with combination monoclonal antibody therapy," the investigators concluded.

Reference:

Study titled, "Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial," published in the Journal of American Medical Association.

DOI: 10.1001/jama.2021.8828

Article Source : JAMA Network

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Beta-blockers Reduce Death, MI, Heart Failure 25% in Mildly Reduced LVEF: Latest Meta-Analysis Presented at ESC Congress 2025

2025-09-12 03:30 GMT

Bamlanivimab reduces risk of COVID-19 Infection: JAMA Study

Bamlanivimab monotherapy reduces the incidence of COVID-19 infection, according to a clinical trial.;

Similar News

AOPT-LTL Therapy Improves Melasma via SCF/c-KIT Pathway Inhibition: Study Finds

taVNS Reduces Postpartum Uterine Contraction Pain After Cesarean Delivery: JAMA

Elevated CAR on POD3 Predicts Prolonged Hospital Stay After Advanced hepatobiliary or pancreatic surgery: Study

15 Percent of COPD Exacerbation Patients Develop Arrhythmias, Tripling In-Hospital Death Risk: Meta-Analysis

Beta-blockers Reduce Death, MI, Heart Failure 25% in Mildly Reduced LVEF: Latest Meta-Analysis Presented at ESC Congress 2025

Gestational Diabetes Tied to Long-Term Thyroid Disorders, Study Finds

At-home blood pressure cuffs-and reminders to use them-key to blood pressure control: JAMA

Greater Kidney Complications in Patients Diagnosed with Type 2 Diabetes Before 40: Study Finds